Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares for the month of March 2026. The filing details a specific share repurchase executed on March 30, 2026, acting through BNP Paribas SA as the broker. The transaction is part of an existing buyback programme established under a non-discretionary agreement announced on February 17, 2026.
Key Financial Metrics
The filing focuses exclusively on share repurchase activity and does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics.
- Shares Purchased (March 30, 2026): 340,000 ordinary shares.
- Lowest Price Paid: 2,045.00 GBp.
- Highest Price Paid: 2,070.00 GBp.
- Volume-Weighted Average Price (VWAP): 2,060.19 GBp.
- Total Shares Purchased Since Feb 17, 2026: 15,881,521 ordinary shares.
- Treasury Shares Held: 255,772,615 ordinary shares.
- Shares in Issue (excluding Treasury): 4,060,407,166 ordinary shares.
- Treasury Voting Rights Percentage: 6.30%.
Material Changes
Following the March 30 transaction, the company's total treasury shareholding increased to 255,772,615 shares. The total number of voting rights attributable to the company remains 4,060,407,166. The filing notes that the purchase was executed across three trading venues: BATE (40,240 shares), CHIX (88,441 shares), and XLON (211,319 shares).
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2025.
Investor Verification Checklist
- Verify the total number of shares held in treasury (255,772,615) against the company's latest capital structure disclosures.
- Confirm the remaining capacity under the non-discretionary buyback agreement announced on February 17, 2026.
- Review the "Risk Factors" in the 2025 Form 20-F for context on the uncertainties affecting the company.
- Check the denominator for voting rights calculations (4,060,407,166) for compliance with FCA Disclosure Guidance and Transparency Rules.